← Back to patent-cliff list
INM-176
Tier C — Watch / tradeINM-176
Scigenics
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Natural product / extract
Type
Targets：Proteins
Brand：Alzhima 176
Indications (approved)：Prostate cancer, Alzheimer's disease
Regional status
US
Phase II
2025-05-07
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of INM-176?
Approved indications include: Prostate cancer, Alzheimer's disease.
When does the INM-176 patent expire?
No public expiry year is available for INM-176 yet; this page updates once verified.
How do I get a quote for INM-176 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30